FDA Approves ZITHROMAX — Pfizer Laboratories Div Pfizer Inc

Pfizer has announced that ZITHROMAX (azithromycin dihydrate), confirmed by the 1997 intravenous approval, remains a cornerstone of its broad-spectrum antibiotic portfolio despite looming patent cliff challenges. The continued relevance of the brand’s IV formulation in treating community-acquired respiratory and skin infections will be critical as the generic Revolution, Inc. gains market share through its March 2021 approved NDA.